
Source briefing
Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 63, Status: Authorised
Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 63, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 63, Status: Authorised
Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 63, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Denbrayce, denosumab, Date of authorisation: 26/06/2025, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Denbrayce, denosumab, Date of authorisation: 26/06/2025, Revision: 4, Status: Authorised
Read →
Source briefing
Women are missing from medicines development: EMA’s roadmap for change
By the end of 2026, EMA will develop a regulatory roadmap to help drive decisive change on how women’s health is considered across medicines development and regulation. This…, Women are still missing: from research and data, prevention, diagnosis…
Read →
Source briefing
Selective serotonin reuptake inhibitors and immune checkpoint blockade in solid tumors: A target trial emulation with pan-cancer transcriptomic analyses
by Po-Huang Chen, Ming-Shen Dai, Mao-Hsuan Huang, Hsin-Yu Chen, Li-Ting Kao, Tina Yi-Jin Hsieh, Hong-Jie Jhou, Cho-Hao Lee Background Preclinical evidence identifies the serotonin transporter (SERT, encoded by SLC6A4) as an immune checkpoint on CD8+ T cells, with selective…
Read →
Source briefing
Medicine shortages and availability issues
Medicine shortages and availability issues
Read →
Source briefing
Human medicines European public assessment report (EPAR): Tafamidis Accord, tafamidis, Date of authorisation: 18/09/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Tafamidis Accord, tafamidis, Date of authorisation: 18/09/2026, Status: Authorised
Read →
Source briefing
From wrist to research: Harnessing smartwatch data for equitable cardiovascular research
by Manpreet Kaur, on behalf of the PLOS Medicine Staff Editors Cardiovascular disease is a leading cause of death, and progress in reducing mortality has stalled, calling for more research. An opportunity lies in harnessing cardiovascular data from…
Read →
Source briefing
Harvard launches $150 million research initiative
University plans range of awards in basic and applied science, seeking to meet ‘moment of remarkable opportunity’
Read →
Source briefing
Reform of the EU pharmaceutical legislation
Reform of the EU pharmaceutical legislation
Read →